logo-loader

Verona Pharma

Receive alerts
Market:
AIM
Market Cap:
£50.56 m
Price
48.00 GBX
Change
0.00%
52 weeks high
120.00
52 weeks low
42.00

Breathtaking Science

At Verona Pharma our vision is to become a leader in developing and commercializing innovative treatments to improve the health and quality of life of the millions of people affected by chronic respiratory diseases.

Overview

Verona Pharma plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs.

Our proprietary lead candidate, ensifentrine (RPL554), is paving the way for a new generation of drugs, with a novel mode of action, and has the potential to provide relief for the many patients suffering from respiratory conditions such as chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and possibly asthma.

Ensifentrine is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 (PDE3 and PDE4), that act as both a bronchodilator and an anti-inflammatory agent in a single compound. There is no therapy currently available that acts as both a bronchodilator and anti-inflammatory in a single compound for the treatment of respiratory diseases. We believe ensifentrine has the potential to be the first novel type of bronchodilator in over forty years.

Verona Pharma is listed on the Nasdaq Global Market and the London Stock Exchange and is supported by a number of large, specialist healthcare focused investors from the US, UK and Europe.

We believe RPL554 has the potential to be the first novel type of bronchodilator in over forty years.

United Kingdom.

David Ebsworth

PhD

Non-Executive Chairman of the Board

Dr. Ebsworth has as served as the Non-Executive Chairman of our board of directors since December 2014. From October 2009 to August 2014, Dr. Ebsworth served as Chief Executive Officer of Vifor Pharma, based in Zürich, the specialty pharma division of Galenica AG Group, a pharmaceutical wholesaler and retailer, and as a member of Galenica’s Executive Committee. In 2012, Dr. Ebsworth was also named as Chief Executive Officer of Galenica and as Chairman of Galenica’s Executive Committee, positions he held until August 2014.  Dr. Ebsworth received a Ph.D. in industrial relations from the University of Surrey.
 

Jan-Anders Karlsson

PhD

Chief Executive Officer and Executive Director

Dr. Karlsson has served as our Chief Executive Officer and on our board of directors since June 2012. From January 2005 to May 2012, Dr. Karlsson was the Chief Executive Officer of S*BIO Pte Ltd, a biotechnology company in Singapore. Previously to S*BIO, Dr. Karlsson was Executive Vice President and head of Pharma Global Research at Bayer Healthcare AG in Germany. Dr. Karlsson received a M.Sc. in pharmacy from Uppsala University and a Doctor of Medical Science (Ph.D.) in clinical experimental pharmacology from the University of Lund.
 

Ken Cunningham

MD

Non-Executive Director

Dr. Cunningham has served as a Non-Executive Director on our board of directors since September 2015.  Dr. Cunningham serves as the non-executive chairman of the board of directors of Abzena plc and non-executive member of the board of directors of Medherant Ltd.  Dr. Cunningham received a degree in medicine from St. Mary’s, Imperial College, London University.
 

Martin Edwards

MD, MBA

Non-Executive Director

Dr. Edwards has served as an Independent Non-Executive Director on our board of directors since April 2019. He has significant experience investing in and contributing to the development of biotech companies in both Europe and the US. Since 2003, Dr. Edwards has held various positions at Novo Holdings, a life sciences investor, and is currently part-time Senior Partner. Dr Edwards serves on the boards of several biotech companies. Earlier in his career, he was Corporate VP and Global Head of Drug Development for Novo Nordisk A/S, where he led all aspects of pre-clinical and clinical drug development. Dr. Edwards trained in physiology and medicine at the University of Manchester. He is a Member of the Royal College of Physicians, a Member with distinction of the Royal College of General Practitioners, a Fellow of the Faculty of Pharmaceutical Medicine and holds a MBA from the University of Warwick.
 

Rishi Gupta J.D

BSc Biochemical Sciences from Harvard College, Bachelors degree in Law from Yale Law School

Non-Executive Director

Mr. Gupta has served as a Non-Executive Director on our board of directors since July 2016.  Since 2002, Mr. Gupta has held various positions at OrbiMed Advisors LLC, a global healthcare investment firm, where he is currently a Private Equity Partner. Mr. Gupta currently is a member of the board of directors of  Avitide, Inc. and Turnstone Biologics, Inc. Mr. Gupta received an A.B. in biochemical sciences from Harvard College and a J.D. from the Yale Law School.
 

Mahendra G. Shah

PhD, MPharm, BSc

Non-Executive Director

Dr. Shah has served as a Non-Executive Director on our board of directors since July 2016.  Since March 2010, Dr. Shah has served as a Managing Director of Vivo Capital, a healthcare investment firm. Dr. Shah is also the founder and Executive Chair of Semnur Pharmaceuticals, Inc., a specialty pharmaceutical company. Dr. Shah serves as a member of the board of directors of Fortis Inc., a specialty pharmaceuticals company, Crinetics Pharmaceuticals, Inc., Soleno Therapeutics, Inc., Impel Neuropharma, Inc., and several other private companies in the biopharmaceutical and biotechnology industries. Dr. Shah received his Ph.D. in industrial pharmacy from St. John’s University and a Master’s Degree in Pharmacy from L.M. College of Pharmacy in Gujarat, India.
 

Andrew Sinclair

Ph.D. in Chemistry and Genetic Engineering at the BBSRC Institute of Plant Science, Norwich, and holds a BSc in Microbiology from King’s College London

Non-Executive Director

Dr. Sinclair has served as a Non-Executive Director on our board of directors since July 2016. Since 2008, Dr. Sinclair has held various positions at Abingworth LLP, a life sciences investment group, where he is currently a Partner and Portfolio Manager. Dr. Sinclair received a Ph.D. in chemistry and genetic engineering at the BBSRC Institute of Plant Science, Norwich, and a B.Sc. in microbiology from King’s College London.
 

Vikas Sinha

CPA

Non-Executive Director

Mr. Sinha has served as a Non-Executive Director on our board of directors since September 2016. Since January 2018, Mr. Sinha has served as an Executive Partner of MPM Capital, Inc., a life sciences investment company. From 2005 to 2016, Mr. Sinha was the Chief Financial Officer of Alexion Pharmaceuticals, Inc., a biotechnology company. Mr. Sinha holds a master's degree in business administration from the Asian Institute of Management. He is also a qualified Chartered Accountant from the Institute of Chartered Accountants of India and a Certified Public Accountant in the United States.
 

Anders Ullman

PhD, MD

Non-Executive Director

Dr. Ullman has served as a Non-Executive Director on our board of directors since September 2015. Since 2016, he has served as Head of the COPD Centre at Sahlgrenska University Hospital, Sweden. From 2013 to 2014, Dr. Ullman was Executive Vice President and Head of Research and Development in the BioScience business unit of Baxter International Inc., a healthcare company, which became Baxalta Inc. From 2007 to 2013, Dr. Ullman was Executive Vice President, Head of Research and Development at Nycomed Pharma Private Limited, which was acquired by Takeda Pharmaceutical Company Limited. Dr. Ullman received a M.D. and a Ph.D. in clinical pharmacology from the University of Gothenburg.

Verona Pharma plc
3 More London Riverside
London SE1 2RE
United Kingdom

E[email protected]
T: +44 (0)203 283 4200

Registered address
One Central Square
Cardiff CF10 1FS
United Kingdom

US Investor relations contact
Westwicke, an ICR Company
E[email protected]
T: +1 203 919 7905

European Investor relations contact
Optimum Strategic Communications
E[email protected]
T: +44 (0)203 950 9144

Nominated adviser and broker
Nplus1 Singer Advisory LLP
One Bartholomew Lane
London EC2N 2AX
United Kingdom

T: +44 (0)203 283 4200

Company Secretary

Ben Harber
Shakespeare Martineau
60 Gracechurch Street
London  EC3V 0HR
United Kingdom

 

UK Nominated Adviser and Broker

Nplus1 Singer Advisory LLP
One Bartholomew Lane
London EC2N 2AXT
United Kingdom

 

Auditors and Reporting Accountants

PricewaterhouseCoopers LLP
3 Forbury Place
23 Forbury Road
> Reading
Berkshire RG1 3JH
United Kingdom

 

UK Share Registry

Computershare Investor Services plc
PO Box 82, The Pavilions
Bridgewater Road
Bristol BS99 7NH
United Kingdom

 

ADS Depositary

Citigroup Depositary Services
388 Greenwich Street
New York, New York 10013
United States

Shareholder information

Capital structure

The Company's issued share capital consists of 105,326,638 ordinary shares with a nominal value of 5 pence each ("Ordinary Shares"), each share having equal voting rights. The Company does not hold any Ordinary shares in treasury and therefore the number of Ordinary Shares with voting rights is 105,326,638.

In accordance with AIM Rule 26, in so far as the Company is aware, the percentage of the Company's issued share capital that is not in public hands is 67.5%. The percentage of the Company's issued share capital held by the Directors and management is 0.5%.

A number of European and US healtchare specialist investment firms have invested in the Company. At 31 December 2018, the interests in excess of 3% of the Company’s issued share capital are as set out in the table.